Ó³»­´«Ã½

Mutation-based score provides a personalized indicator of disease severity and progression risk, could help inform early intervention strategies

The winners are Carl June, Bruce Levine, Isabelle Rivière, and Michel Sadelain, who developed technology that reprograms patients’ immune systems to target cancer, leading to several FDA-approved treatments given to over 45,000 cancer patients, including many who had exhausted all other options and thousands who experienced remissions.

The effort will engage with patients, empowering them to share their unique health data with scientists to accelerate research.

Researchers find four coordinated gene expression programs in immune cells from glioma tumors, including two that could lead to immunotherapy resistance.

Targeting the PELO gene could be a way to kill tumor cells in cancers with one of two common genetic mutations.

Wolu Chukwu talks about how she brings a community-first focus to her work in cancer genetics. 

Slow-growing glioma tumors become more aggressive when their cells shift identities and acquire new genetic mutations.

Ó³»­´«Ã½ and Mass General researcher Alexandra-Chloé Villani and Mass General oncologist Kerry Reynolds describe their pioneering effort to better understand, diagnose, and manage dangerous complications from cancer immunotherapy. 

Myocarditis is driven by a different immune response than the anti-tumor one, suggesting that the serious complication could one day be managed without halting cancer therapy.

The team compared different single-cell and spatial profiling methods to explore the diversity of cells in metastatic breast cancer biopsies.